quinazolines has been researched along with Ovarian Neoplasms in 175 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.57) | 18.7374 |
| 1990's | 10 (5.71) | 18.2507 |
| 2000's | 54 (30.86) | 29.6817 |
| 2010's | 95 (54.29) | 24.3611 |
| 2020's | 15 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Anastasia, A; Arnold, S; Bani, MR; Barry, ST; Bizzaro, F; Cavallaro, U; Damia, G; Fuso Nerini, I; Galbiati, A; Ghilardi, C; Giavazzi, R; Guana, F; Guffanti, F; Hattersley, MM; Leo, E; Minoli, L; Ostano, P; Ramos-Montoya, A; Russo, M; Taylor, MA; Urosevic, J; Williamson, SC | 1 |
| Bindhya, S; Ganesan, TS; Joshua, T; Krishnapriya, S; Manasa, P; Murhekar, K; Nagare, RP; Shabna, A; Sidhanth, C; Sneha, S | 1 |
| Alvisi, MF; Benedetti Panici, P; Biagioli, E; Bologna, A; Carlucci, L; Colombo, N; DeCensi, A; Fossati, R; Lapresa, M; Lissoni, AA; Mancari, R; Nicoletto, MO; Palaia, I; Poli, D; Rulli, E; Tasca, G; Tettamanzi, F; Tognon, G; Tomao, F; Torri, V | 1 |
| Balkwill, FR; Berlato, C; Gopinathan, G; Laforets, F; Lakhani, A; Maniati, E; Pedrosa, AR; Pegrum, C; Szabova, L | 1 |
| Brown, J; Chapman, J; Diaz, JP; Dymond, M; Ghamande, S; Kendrick, J; Kumar, S; Lee, JM; Liu, JF; Lowe, ES; Milenkova, T; Moore, RG; Park, MS; Slomovitz, BM; Tewari, KS | 1 |
| Choi, DK; Kim, JH; Kim, JW; Lee, DS; Lee, H; Min, SH; Yu, JH | 1 |
| Costi, MP; D'Arca, D; Ferrari, S; Gozzi, G; Lauriola, A; Leo, E; Losi, L; Maretti, E; Marverti, G; Pacifico, S; Ponterini, G; Sacchetti, F; Severi, L | 1 |
| Kim, JW; Lee, DS; Lee, H; Min, SH | 1 |
| Arthur-Darkwa, E; Burnett, E; Counsell, N; El-Khouly, F; Elyashiv, O; Farrelly, L; Feeney, A; Gourley, C; Jayson, GC; Ledermann, J; Macdonald, I; Mileshkin, L; Neto, A; Nicum, S; Parmar, G | 1 |
| Kwon, M; Lee, DW; Lee, HN; Lee, W | 1 |
| Fujii, T; Hamamoto, R; Honjoh, H; Inoue, F; Kaneko, S; Kashiyama, T; Kojima, M; Komatsu, M; Kukita, A; Miyamoto, Y; Mori-Uchino, M; Osuga, Y; Sone, K; Taguchi, A; Takahashi, Y; Tanikawa, M; Tsuruga, T; Wada, M; Wada-Hiraike, O | 1 |
| Collins, L; Dobbie, S; Dunn, R; Holmes, J; Mansouri, A; McGregor, N; Nicum, S | 1 |
| Deane, E; Embleton-Thirsk, AC; Farrelly, L; Friedlander, M; González-Martín, A; Hirte, H; Jayson, GC; Kaplan, RS; Kaye, SB; Ledermann, JA; Oza, A; Parmar, MKB; Perren, TJ; Popoola, B; Rustin, GJS; Swart, AM; Vaughan, M | 1 |
| Cardin, DB; Glazer, PM; Grossman, SR; Ivy, SP; Kato, S; Kim, JW; LoRusso, PM; Shyr, Y; Vaishampayan, UN | 1 |
| Gorski, JW; Kolesar, JM; Lin, N; Liu, J; McCorkle, JR; McDowell, AB; Riggs, MB; Ueland, FR; Wang, C | 1 |
| Brown, JM; Brundage, MD; Cook, A; Embleton, AC; Kaplan, RS; Ledermann, JA; Qian, W; Raja, FA; Stark, DP; Swart, AMW; Velikova, G | 1 |
| Jin, J; Lai, W; Lin, Q; Shao, G; Shao, Q; Wan, X; Wei, Y; Xue, J; Zhang, L; Zou, S | 1 |
| Jean-Claude, B; Thibault, B | 1 |
| Antony, J; El-Bahrawy, M; Gabra, H; Karali, E; Louis, LS; McKie, AB; Okon, IS; Recchi, C; Stebbing, J; Vaughan, S; Zanini, E | 1 |
| Guo, R; Jin, S; Min, H; Shu, Y; Wen, W; Wu, H; Xu, T; Zhang, Z | 1 |
| Banerjee, S; George, A; Marquina, G; Orbegoso, C | 1 |
| Li, B; Li, Y; Liu, Z; Shu, T; Wu, X | 1 |
| Bown, JL; Deeni, YY; Kankia, IH; Khalil, HS; Langdon, SP; Moult, PR | 1 |
| Zhang, Y | 1 |
| Bryant, A; Gaitskell, K; Goodall, RJ; Lyons, TJ; Morrison, J; Thoma, C; Wiggans, AJ | 1 |
| Bonam, M; Ivy, SP; Killiam, B; Kohn, EC; Lee, JM; Liu, JF; Mari, K; Milenkova, T; Phillips, R; Strock, E | 1 |
| Barry, WT; Birrer, M; Buckanovich, RJ; Buss, MK; Curtis, J; Fleming, GF; Hurteau, J; Ivy, SP; Kohn, EC; Lee, JM; Liu, JF; Luo, W; Matulonis, UA; Nattam, SR; Rimel, BJ; Whalen, C | 1 |
| Gonzalez-Martin, A; Lorusso, D; Pignata, S | 1 |
| Jung, JH; Kim, BI; Kim, JH; Kim, SH; Lee, J; Nam, M; Shim, B; Sim, DY | 1 |
| Annunziata, CM; Cao, L; Cimino-Mathews, A; Figg, WD; Gatti-Mays, M; Houston, ND; Kohn, EC; Lee, JM; Lee, MJ; Lipkowitz, S; Mikkilineni, L; Nichols, E; Peer, C; Sharma, R; Trepel, JB; Zimmer, AS | 1 |
| Deane, E; Embleton-Thirsk, A; Farrelly, L; Kaplan, R; Ledermann, J; Parker, J; Parmar, M; Popoola, B; Rustin, G; Sydes, M; Townsend, S | 1 |
| Li, XZ; Ma, YX | 1 |
| Birrer, M; Buss, MK; Dahlberg, SE; Fleming, GF; Ivy, P; Lee, H; Liu, JF; Matulonis, UA; Tolaney, SM; Tyburski, K; Whalen, C; Winer, E | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Garber, C; Keith, C; Kohn, E; Lam, G; Mascia, F; Steinberg, SM; Yuspa, SH | 1 |
| du Bois, A; Elser, G; Harter, P; Hilpert, F; Kimmig, R; Kurzeder, C; Rau, J; Sehouli, J | 1 |
| Atkey, N; Bolton, LM; Cree, IA; Dyson, M; Glaysher, S; Johnson, P; Torrance, C | 1 |
| Becker, MA; Farzan, T; Haluska, P; Harrington, SC; Hou, X; Kalli, KR; Krempski, JW; Weroha, SJ; Wong, TW | 1 |
| Chai, C; Choolani, M; Chu, YS; Chung, VY; Huang, RY; Kuay, KT; Lai, HC; Lee, YF; Low, JJ; Matsumura, N; Mori, S; Ng, AH; Pietschmann, E; Sim, WJ; Tan, TZ; Thiery, JP; Wong, MK | 1 |
| Cho, S; Choi, DL; Choi, HE; Choi, HW; Huang, M; Jang, SJ; Kim, KS; Lee, JY; Lee, KT; Rhim, H; Rim, HK | 1 |
| Buck, M; Casado, A; Coens, C; Colombo, N; Curé, H; Despierre, E; Favier, L; Ferrero, A; Green, J; Hall, M; Jimeno, A; Joly, F; Katsaros, D; Lesoin, A; Marth, C; Pujade-Lauraine, E; Ray-Coquard, I; Reed, NS; Reinthaller, A; Steer, CB; Vergote, IB | 1 |
| Bertrand, M; Correa, RJ; DiMattia, GE; Fazio, EN; McGee, J; Peart, TM; Préfontaine, M; Shepherd, TG; Sugimoto, A; Valdes, YR | 1 |
| Downey, A; Levinson, B; Liebes, L; Muggia, F; Tiersten, A; Warner, E | 1 |
| Anderson, GL; Bonebrake, AJ; Chambers, SK; Coleman, RL; Delmore, JE; Hu, W; Markman, M; Moon, J; Sood, AK | 1 |
| Cai, Q; Hong, S; Jiang, W; Xu, C; Yu, Y; Zhang, M; Zhang, X | 1 |
| Fu, J; Gou, W; Han, X; Li, L; Li, X; Yang, T; Zhang, Y | 1 |
| Casado, A; Coens, C; Jimeno, A; Vergote, I | 1 |
| Freidlin, B; Korn, EL | 1 |
| Ambartsumian, N; Andersen, SH; Brix, DM; Bundgaard Clemmensen, K; Jäättelä, M; Kallunki, T; Rafn, B | 1 |
| Banerjee, S; Clamp, A; Dawson-Athey, L; Earl, H; Feeney, A; Hall, G; Hall, M; James, L; Kaye, SB; Khan, I; Kristeleit, R; Lawrence, C; Ledermann, JA; McNeish, IA; Persic, M; Raja, F; Webber, L | 1 |
| Barry, WT; Birrer, M; Buckanovich, RJ; Buss, MK; Fleming, GF; Hurteau, J; Ivy, SP; Kohn, EC; Lee, H; Lee, JM; Liu, JF; Luo, W; Matulonis, UA; Nattam, S; Obermayer, L; Quy, P; Rimel, B; Whalen, C; Winer, EP | 1 |
| Muggia, F; Teplinsky, E | 1 |
| Cao, H; He, Q; Liu, Y; Lou, S; Lv, W; Ma, Y; Qi, X; Shao, X; Yang, X; Ying, M | 1 |
| Gao, Q; Gong, C; Jin, P; Liu, Y; Ma, D; Wei, X; Xu, S; Yang, Z; Zhang, T; Zhou, X | 1 |
| Balkwill, FR; Bowtell, DD; Everitt, G; Gopinathan, G; Grose, R; Hochhauser, D; Hollingsworth, RE; Kulbe, H; Milagre, CS; Thompson, RG; Zhong, H | 1 |
| Schmidt, C | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Biagi, J; Fleming, GF; Hirte, H; Ivy, SP; Lheureux, S; McGill, S; Morgan, R; Oza, AM; Sugimoto, A; Wang, L | 1 |
| Buettner, R; Dellinger, TH; Han, ES; Horne, D; Hsieh, MY; Jove, R; Liu, L; Tian, Y; Wen, W; Wu, J; Yim, JH | 1 |
| Belotti, D; Bettolini, R; Bizzaro, F; Cesca, M; Decio, A; Giavazzi, R; Porcu, L; Taraboletti, G; Ubezio, P | 1 |
| Cai, Y; Li, GF; Liang, QY; Liu, ST; Liu, Y; Song, ZH; Sun, YB; Wang, SQ; Wang, YT; Yang, FH; Zhao, BX | 1 |
| Qiang, WA; Tan, W; Wang, SP; Wang, YT; Zhong, ZF | 1 |
| Bracchi, C; De Medici, C; Gasparri, ML; Imboden, S; Marchetti, C; Mueller, MD; Muzii, L; Palaia, I; Panici, PB; Papadia, A; Ruscito, I | 1 |
| Ivy, SP; Kohn, EC; Lee, JM; Liu, JF; Matulonis, UA | 1 |
| Chen, TC; Chen, YC; Chien, CC; Wu, MS | 1 |
| Clark, E; Cook, A; Eisenhauer, E; Embleton, AC; Farrelly, L; Friedlander, M; González-Martín, A; Hirte, H; Jayson, GC; Kaplan, RS; Kaye, SB; Ledermann, JA; Parmar, MKB; Perren, TJ; Raja, F; Rustin, GJS; Stark, D; Swart, AM; Vaughan, M | 1 |
| Cao, Z; Jin, X; Li, W; Wei, L | 1 |
| Bastola, P; Chien, J; Neums, L; Schoenen, FJ | 1 |
| Coldren, CD; Geraci, MW; Heasley, LE; Helfrich, BA; Mickler, EA; Nakachi, I; Olson, CJ; Rice, JL; Spillman, MA; Stearman, RS | 1 |
| Chang, HM; Cheng, JC; Leung, PC; So, WK; Xiong, S | 1 |
| Bai, Y; Black, J; Carvajal-Hausdorf, DE; Rimm, DL; Santin, AD; Schalper, KA | 1 |
| Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK | 1 |
| Alvarez, RD; Barnes, MN; Estes, JM; Kimball, KJ; Kirby, TO; Koch, KM; Matei, DE; Numnum, TM; Zamboni, WC | 1 |
| Ferlini, C; Mozzetti, S; Riccardi, A; Riccardi, R; Servidei, T | 1 |
| Balko, JM; Black, EP | 1 |
| Choi, WS; Han, JW; Jeong, KJ; Kang, JK; Kim, YK; Lee, HY; Lee, KB; Park, CG; Park, SY; Seo, JH | 1 |
| Auersperg, N; Klausen, C; Leung, PC | 1 |
| Berkenblit, A; Berlin, S; Campos, S; Cannistra, SA; Hill, M; Horowitz, N; Humphreys, BD; Ivy, P; Krasner, C; Lee, H; Lee, J; Matulonis, UA; Penson, RT; Roche, M; Sullivan, L; Tran, C; Tyburski, K; Whalen, C; Zarwan, C | 1 |
| Berndt, A; Cesca, M; D'Incalci, M; Frapolli, R; Giavazzi, R; Kosmehl, H; Richter, P; Ryan, AJ; Scarlato, V | 1 |
| Berlin, ST; Humphreys, BD; Ivy, P; Matulonis, UA; Penson, RT; Robinson, ES; Tyburski, K | 1 |
| Annunziata, CM; Calvo, K; Choyke, P; Kimm, D; Kohn, EC; Kotz, H; Minasian, L; Steinberg, SM; Walker, AJ; Wood, BJ; Yu, M | 1 |
| Bougnoux, P; Carrasco, AT; Fumoleau, P; Joly, F; Kerbrat, P; Lhommé, C; Pautier, P; Petit, T; Ringeisen, F; Rixe, O | 1 |
| Hao, YY; Iwamori, M; Li, FF; Lin, B; Liu, DW; Liu, JJ; Qi, Y; Zhang, SL; Zhu, LC | 1 |
| Ballinari, D; Brasca, MG; Casale, E; Ciomei, M; Colombo, N; Croci, V; Fiorentini, F; Isacchi, A; Longo, A; Mercurio, C; Panzeri, A; Pastori, W; Pevarello, P; Roussel, P; Traquandi, G; Volpi, D; Vulpetti, A | 1 |
| Hudson, LG; Ning, Y; Zeineldin, R | 1 |
| Ellard, SL; Fisher, B; Grimshaw, R; Hirte, H; Oza, A; Seymour, L; Swenerton, K; Tsao, M | 1 |
| Blank, SV; Chen, HX; Christos, P; Curtin, JP; Goldman, N; Liebes, L; Muggia, FM; Runowicz, CD; Sparano, JA | 1 |
| Alberts, DS; Baker, AF; Brewer, MA; Chambers, SK; Clouser, MC; Cohen, JL; Cui, H; Gordon, AN; Gordon, MS; Hatch, KD; Isaacs, JD; Janicek, MF; Nagle, RB; Roe, DJ; Wright, HM | 1 |
| Goff, B; Holmberg, LA; Veljovich, D | 1 |
| Murphy, M; Stordal, B | 1 |
| Dakhilm, SR; Haluska, P; Hartmann, LC; Keeney, GL; Moore, DF; Oberg, AL; Peethambaram, PP; Rowland, KM; Weroha, SJ; Ziegler, KL | 1 |
| Brahimi, F; Golabi, N; Huang, Y; Jean-Claude, BJ; Larroque-Lombard, AL; Qiu, Q; Rachid, Z | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Albini, A; Anzà, C; Baravelli, M; Bucci, EO; Cammarota, R; Cesana, E; Donatelli, F; Noonan, DM | 1 |
| Anees, M; Dolznig, H; El-Gazzar, A; Grunt, TW; Holcmann, M; Horak, P; Horvat, R; Krainer, M; Pils, D; Savarese-Brenner, B; Schemper, M; Schöfer, C; Sibilia, M; Vanhara, P; Wittinger, M; Zeillinger, R | 1 |
| Armstrong, DK; Carolla, RL; Fischer, EG; Garcia, AA; Godwin, AK; Lankes, HA; Leslie, KK; Liepman, MK; Mannel, RS; Sill, MW; Spirtos, NM | 1 |
| Bellomo, C; Leporatti, S; Lorusso, V; Lvov, YM; Maffia, M; Rinaldi, R; Tinelli, A; Vergara, D; Vergaro, V; Zhang, X | 1 |
| Akar, U; Bartholomeusz, C; Esteva, FJ; Kazansky, A; Kigawa, J; Kondo, K; Krishnamurthy, S; Lee, J; Liu, P; Oishi, T; Saso, H; Ueno, NT | 1 |
| Alberti, C; Canevari, S; Ditto, A; Ferri, R; Pinciroli, P; Sensi, M; Tomassetti, A; Umezawa, K; Valeri, B | 1 |
| Chouhan, BS; Garofalo, A; Giridhar, R; Grande, F; Naik, PP; Neamati, N; Yadav, MR | 1 |
| Ji, Y; Lu, Y; Mills, GB; Müller, P; Nieto-Barajas, LE | 1 |
| Kurachi, H; Ohmichi, M; Ohta, T; Shibuya, T; Takahashi, K; Takahashi, T; Tsutsumi, S | 1 |
| Alli, C; Alzani, R; Avanzi, N; Ballinari, D; Beria, I; Cappella, P; Caruso, M; Casolaro, A; Ciavolella, A; Cucchi, U; De Ponti, A; Felder, E; Fiorentini, F; Galvani, A; Gianellini, LM; Giorgini, ML; Isacchi, A; Lansen, J; Moll, J; Pesenti, E; Rizzi, S; Rocchetti, M; Sola, F; Valsasina, B | 1 |
| Bagnato, A; Cianfrocca, R; Di Castro, V; Rosanò, L; Spinella, F; Tocci, P | 1 |
| Bénard, J; Bidart, JM; Farinotti, R; Forestier, F; Gil, S; Jovelet, C | 1 |
| Baird, RD; Barton, DP; Kaye, SB; Khan, AZ; Moreno, V; Vitfell-Pedersen, J; Yap, TA | 1 |
| Gui, T; Shen, K | 1 |
| Caparelli, F; Hoff, PM; Sahade, M | 1 |
| Bezler, M; Hengstler, JG; Ullrich, A | 1 |
| Azzam, D; da Silva, T; Gilbert, CA; Hevia-Paez, P; Ince, TA; Levin, ER; Lu, Y; Mills, GB; Pedram, A; Rabinovich, B; Reis, IM; Simpkins, F; Slingerland, JM; Sun, J; Ullmer, W; Verhaak, RG; Xu, XX; Yang, JY | 1 |
| Jain, A; Ryan, PD; Seiden, MV | 1 |
| Busch, TM; Cengel, KA; Edmonds, C; Gallagher-Colombo, SM; Hagan, S | 1 |
| Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
| Harada, T; Itamochi, H; Kato, M; Kigawa, J; Kudoh, A; Naniwa, J; Nishimura, M; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N | 1 |
| Adam-Klages, S; Arnold, N; Caliebe, A; Eckmann-Scholz, C; Fredrik, R; Hilpert, F; Ma, Y; Schem, C; Sebens, S; Weimer, J | 1 |
| Goldberg, GL; Hazan, R; Horwitz, SB; Hou, JY; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L; Samaweera, L | 1 |
| Fujimura, M; Hidaka, T; Saito, S | 1 |
| Fischer, DC; Gabriel, B; Kieback, DG | 1 |
| Ranson, M | 1 |
| Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H | 1 |
| Baselga, J; Hammond, LA | 1 |
| Grunt, TW | 1 |
| Lorusso, PM | 1 |
| Vasey, PA | 1 |
| Arbel, R; Ben-Bassat, H; Hartzstark, Z; Klein, BY; Laufer, N; Levitzki, R; Rojansky, N | 1 |
| Hainsworth, J; Janssens, J; Vergote, I | 1 |
| Carson, L; Clarke-Pearson, D; Douglass, EC; Holloway, R; Kao, MS; Moore, M; Rader, JS; Wiznitzer, I | 1 |
| Pérez-Soler, R | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Benepal, TS; Judson, I | 1 |
| Gaiger, A; Grunt, TW; Kainz, B; Puckmair, K; Tomek, K | 1 |
| Lanzi, C; Supino, R; Zanchi, C; Zuco, V; Zunino, F | 1 |
| Bagnato, A; Di Castro, V; Elia, G; Natali, PG; Rosanò, L; Spinella, F | 1 |
| Blank, SV; Chang, R; Muggia, F | 1 |
| Arciero, CA; Chen, X; Darcy, KM; Decesare, SL; Godwin, AK; Lee, RB; Lewandowski, G; Schilder, RJ; Sill, MW; Wu, H | 1 |
| Bidart, JM; Duvillard, P; Lacroix, L; Motté, N; Pautier, P; Saulnier, P; Soria, JC | 1 |
| Bavetsias, V; Forster, MD; Gibbs, DD; Green, M; Henderson, E; Jackman, AL; Mitchell, F; Raynaud, F; Theti, DS; Valenti, M; Wood, N | 1 |
| Fishman, DA; Kang, S; Luo, R; Meng, Y; Smicun, Y | 1 |
| Sabbatini, P | 1 |
| Brose, MS; Flaherty, KT | 1 |
| Di, W; Healey, S; Kouttab, N; Qiu, L; Sun, Y; Wan, Y; Wanebo, H; Yan, B; Zhou, C | 1 |
| Ajose-Adeogun, A; Coley, HM; Modjtahedi, H; Shotton, CF; Thomas, H | 1 |
| du Bois, A; Gropp, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Meier, W; Pfisterer, J; Schmalfeldt, B; Sehouli, J; Stähle, A; Wagner, U | 1 |
| Gaiger, A; Grunt, TW; Kainz, B; Köhler, G; Puckmair, K; Rünzler, D; Tomek, K; Wagner, R; Zielinski, CC | 1 |
| Espina, V; Godwin, AK; Hussain, MM; Kohn, EC; Kwitkowski, V; Liel, MS; Minasian, L; Posadas, EM; Steinberg, SM; Wood, BJ | 1 |
| Auer, D; Daxenbichler, G; Egle, D; Marth, C; Rössler, J; Vergote, I; Zeimet, AG | 1 |
| Feng, Y; Liu, N; Lu, M; Lu, SH; Song, X; Yuan, XF | 1 |
| Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Spinella, F; Tortora, G | 1 |
| Brown, J; Gaikwad, A; Ramondetta, LM; Smith, JA; Stewart, CF; Wolf, JK; Yu, J | 1 |
| Armstrong, DK; Brahmer, JR; Carducci, MA; Chen, P; Das, S; Desai, A; Fackenthal, DL; Fleming, GF; Janisch, L; Jiang, X; Karrison, T; Liu, W; Poonkuzhali, B; Ramirez, J; Ratain, MJ; Rudin, CM; Schuetz, E; Vokes, EE | 1 |
| Amaral, A; Cao, C; Chu, W; Di, W; Kivlin, R; Lu, S; Sowa, A; Wan, Y; Yang, H | 1 |
| Faoro, L; Fleming, GF; Friberg, G; Kasza, K; Morgan, RJ; Nimeiri, HS; Oza, AM; Salgia, R; Stadler, WM; Vokes, EE | 1 |
| Bull Phelps, SL; Lea, JS; Miller, DS; Peyton, MJ; Schorge, JO; Shigematsu, H; Xiang, LL | 1 |
| Carty, K; Gabra, H; Gore, M; Guastalla, JP; Kaye, S; Lauraine, EP; Paul, J; Rustin, G; Vasey, PA; Wilson, R | 1 |
| Aherne, GW; Boyle, FT; Brown, M; Gibson, W; Hardcastle, A; Jackman, AL; Kelland, LR; Kimbell, R | 1 |
| Calvert, AH; Freemantle, SJ; Jackman, AL; Kelland, LR; Lunec, J | 1 |
| Jansen, G; Peters, GJ; Pinedo, HM; Rijnboutt, S; Schornagel, JH; Westerhof, GR | 1 |
| Aherne, GW; Hardcastle, A; Jackman, AL; Kelland, LR; Kimbell, R | 1 |
| Harrap, KR | 1 |
| Azab, M; Cassidy, J; Earl, HM; Gore, ME; Mansi, J; Seymour, L; Tattersall, M | 1 |
| Buquet-Fagot, C; Djelloul, S; Gespach, C; Mester, J; Raymond, E | 1 |
| Blessing, JA; Homesley, HD; Muggia, FM; Sorosky, J | 1 |
| Bartlett, JM; Gordge, P; Langdon, SP; Leake, RE; Macleod, KG; Miller, EP; Miller, WR; Rabiasz, G; Rae, AL; Simpson, BJ; Smyth, J | 1 |
| Assaraf, YG; Borst, P; Broxterman, HJ; Hooijberg, JH; Jansen, G; Kool, M; Noordhuis, P; Peters, GJ; Pinedo, HM; Scheper, RJ | 1 |
| Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW | 1 |
| Bagnato, A; Catt, KJ; Tecce, R; Vacca, F | 1 |
| Bennett, TA; Bergmann-Leitner, ES; Hacker, NF; Stetler-Stevenson, WG; Stromberg, K | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; Damiano, V; Fontanini, G; Melisi, D; Tortora, G; Veneziani, BM; Zunino, F | 1 |
| Chan, E; Cherrington, JM; Christensen, JG; Cui, J; Liu, L; Mendel, DB; Schreck, RE; Sun, L; Wang, X; Wei, J; Yang, C | 1 |
| Bamburg, JR; Bedford, JS; Bernstein, BW; Jha, MN | 1 |
| Langdon, SP; Macleod, KG; Ritchie, A; Sewell, JM; Smyth, JF | 1 |
| Aherne, GW; Brunton, L; Jackman, AL; Kimbell, R; Melin, CJ; Theti, DS; Walton, M | 1 |
| Assaraf, YG; Molina, A; Schimke, RT | 1 |
20 review(s) available for quinazolines and Ovarian Neoplasms
| Article | Year |
|---|---|
The role of Cediranib in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Drug Evaluation, Preclinical; Female; Humans; Ovarian Neoplasms; Quinazolines | 2017 |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2018 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
Topics: Adenocarcinoma, Mucinous; Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Endometrial Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Ovarian Neoplasms; Quinazolines; Trastuzumab; Uterine Neoplasms | 2014 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Cediranib in ovarian cancer: state of the art and future perspectives.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2016 |
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2016 |
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cetuximab; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panitumumab; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Sarcoma | 2012 |
Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Immunotoxins; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2002 |
ZD1839 (Iressa): for more than just non-small cell lung cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Controlled Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome | 2002 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2003 |
ZD9331: discovery to clinical development.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Neoplasms; Ovarian Neoplasms; Quinazolines; Thymidylate Synthase | 2005 |
Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2006 |
Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.
Topics: Animals; Antineoplastic Agents; Cisplatin; Drug Resistance; Female; Humans; Leukemia L1210; Mice; Neoplasm Transplantation; Organoplatinum Compounds; Ovarian Neoplasms; Quinazolines; Structure-Activity Relationship; Thiophenes; Thymidylate Synthase | 1995 |
A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gene Expression; Humans; Ovarian Neoplasms; Peptide Synthases; Quinazolines; RNA, Messenger; RNA, Neoplasm; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2002 |
43 trial(s) available for quinazolines and Ovarian Neoplasms
| Article | Year |
|---|---|
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Phthalazines; Piperazines; Quinazolines | 2022 |
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherap
Topics: Adult; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2021 |
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol.
Topics: Clinical Trials, Phase II as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines | 2021 |
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction | 2017 |
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Germ-Line Mutation; Humans; Hypertension; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum Compounds; Progression-Free Survival; Quinazolines; Response Evaluation Criteria in Solid Tumors; Time Factors | 2019 |
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capsules; Carcinoma, Ovarian Epithelial; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Receptors, Vascular Endothelial Growth Factor; Tablets; Treatment Outcome | 2013 |
Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.
Topics: Animals; Antineoplastic Agents; Blood Cell Count; Chemokines; Disease Models, Animal; ErbB Receptors; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Inflammation Mediators; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Ovarian Neoplasms; Quinazolines; RNA, Messenger; Skin; Translational Research, Biomedical | 2013 |
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2013 |
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Ca
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Signal Transduction; Watchful Waiting | 2014 |
Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Collagen; Epitopes; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Neoplasm Invasiveness; Ovarian Neoplasms; Quinazolines; Topotecan | 2014 |
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Quinazolines; Taxoids; Treatment Outcome | 2014 |
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Quinazolines; Retroperitoneal Neoplasms | 2014 |
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2014 |
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines | 2015 |
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Quinazolines; Treatment Outcome | 2016 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nitriles; Ovarian Neoplasms; Quinazolines; Triazoles | 2008 |
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines | 2008 |
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Treatment Outcome | 2009 |
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antineoplastic Agents; Blood Pressure; Carcinoma; Chi-Square Distribution; Female; Humans; Hypertension; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Proteinuria; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cystadenocarcinoma, Serous; Drug Administration Schedule; ErbB Receptors; Female; Humans; Middle Aged; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Recurrence; Signal Transduction; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gefitinib; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines | 2010 |
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Carboplatin; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines | 2010 |
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Gene Amplification; Genes, erbB-1; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Young Adult | 2010 |
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Likelihood Functions; Ovarian Neoplasms; Platinum Compounds; Prognosis; Quinazolines; Treatment Outcome; Tumor Microenvironment; Up-Regulation; Vascular Endothelial Growth Factor A | 2010 |
Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2011 |
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Receptor, ErbB-2; Survival Rate; Topotecan | 2011 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Disease-Free Survival; ErbB Receptors; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polymorphism, Genetic; Quinazolines | 2012 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome | 2002 |
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Taxoids; Treatment Outcome | 2003 |
A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Quinazolines | 2003 |
A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Quinazolines | 2003 |
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Catalytic Domain; Cloning, Molecular; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Polymerase Chain Reaction; Protein Structure, Tertiary; Quinazolines; Recurrence; Time Factors; Treatment Outcome | 2005 |
Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Paclitaxel; Quinazolines; Treatment Outcome | 2006 |
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gefitinib; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Patient Compliance; Quinazolines; Tamoxifen; Taxoids | 2007 |
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Prospective Studies; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Time Factors; Treatment Outcome | 2007 |
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Selection; Peritoneal Neoplasms; Quinazolines; Safety; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2008 |
A phase II study of Tomudex in relapsed epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Quinazolines; Remission Induction; Thiophenes | 1995 |
Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Metastasis; Ovarian Neoplasms; Platinum Compounds; Quinazolines; Thiophenes; Thymidylate Synthase | 1998 |
112 other study(ies) available for quinazolines and Ovarian Neoplasms
| Article | Year |
|---|---|
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mice, Nude; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Signal Transduction; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2021 |
LASP-1 interacts with ErbB2 in ovarian cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adult; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cohort Studies; Cytoskeletal Proteins; Female; HEK293 Cells; Humans; Lapatinib; LIM Domain Proteins; Middle Aged; Ovarian Neoplasms; Phosphorylation; Plasmids; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection | 2022 |
Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Indoles; Interleukin-6; Mice; Ovarian Neoplasms; Programmed Cell Death 1 Receptor; Quinazolines; Tumor Microenvironment | 2022 |
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
Topics: Adolescent; Adult; Bevacizumab; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Germ Cells; Germ-Line Mutation; Humans; Indoles; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines | 2022 |
Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway.
Topics: Apoptosis; beta Catenin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Down-Regulation; Female; G1 Phase; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplastic Stem Cells; Ovarian Neoplasms; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-4; Receptors, Notch; Signal Transduction; Spheroids, Cellular; STAT5 Transcription Factor | 2020 |
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fluorouracil; Humans; Liposomes; Ovarian Neoplasms; Peptide Fragments; Polyethylene Glycols; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2020 |
Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness.
Topics: AC133 Antigen; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Dihydropyridines; Female; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Nanog Homeobox Protein; Neoplastic Stem Cells; Nitrobenzenes; Ovarian Neoplasms; Piperazines; Quinazolines; STAT5 Transcription Factor; Treatment Outcome; Tumor Suppressor Proteins; Wnt Signaling Pathway | 2020 |
Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells.
Topics: Acetophenones; Benzopyrans; Cell Line, Tumor; Cell Survival; Female; Forkhead Box Protein M1; GTP Phosphohydrolases; Humans; Membrane Proteins; Ovarian Neoplasms; Pyridines; Quinazolines; Quinolones; Signal Transduction; Thiophenes | 2021 |
Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Histones; Humans; Inhibitory Concentration 50; Lysine; Ovarian Neoplasms; Prognosis; Quinazolines; RNA, Small Interfering; Transfection; Up-Regulation | 2020 |
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.
Topics: Adenocarcinoma; Female; Humans; Mutation; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Proteins; Ovarian Neoplasms; Quinazolines | 2021 |
Inactivation of EGFR/AKT signaling enhances TSA-induced ovarian cancer cell differentiation.
Topics: Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tyrphostins | 2017 |
Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Movement; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Molecular Targeted Therapy; Neoplasm Invasiveness; Ovarian Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; src-Family Kinases; Tumor Cells, Cultured | 2017 |
The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
Topics: Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines | 2017 |
Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Cystadenocarcinoma, Serous; Down-Regulation; Female; HEK293 Cells; Humans; Lapatinib; Mice; Mice, Nude; Middle Aged; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor; Ubiquitin-Protein Ligases | 2017 |
NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; MCF-7 Cells; NF-E2-Related Factor 2; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Tetrahydronaphthalenes | 2017 |
Marsdenia Tenacissima Extract Inhibits Proliferation and Promotes Apoptosis in Human Ovarian Cancer Cells.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; China; Cyclin B1; Cyclin D1; Down-Regulation; Female; Humans; Marsdenia; Ovarian Neoplasms; Plant Extracts; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
Technology Applications: Use of Digital Health Technology to Enable Drug Development.
Topics: Biomedical Technology; Diarrhea; Drug Development; Early Diagnosis; Female; Humans; Hypertension; Mobile Applications; Ovarian Neoplasms; Patient Portals; Patient Satisfaction; Pilot Projects; Quinazolines; Research Design; Surveys and Questionnaires; Telemedicine | 2018 |
Chemotherapy-free treatments: are we ready for prime time?
Topics: Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Progression-Free Survival; Quinazolines; Time | 2019 |
Inhibition of JAK2/STAT3 and activation of caspase‑9/3 are involved in KYS05090S‑induced apoptosis in ovarian cancer cells.
Topics: A549 Cells; Caspase 3; Caspase 9; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Janus Kinase 2; Ovarian Neoplasms; Phosphorylation; Protein Transport; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2019 |
Mechanism of Cediranib-Olaparib Combo Revealed.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Down-Regulation; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Rad51 Recombinase | 2019 |
Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Data Accuracy; Data Collection; Double-Blind Method; Drug Approval; Female; Humans; Marketing; Ovarian Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies | 2019 |
[Effect of aurora kinase B inhibitor AZD1152 in the treatment of cisplatin-resistant ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Humans; In Situ Hybridization, Fluorescence; Organophosphates; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Telomerase; Time Factors | 2013 |
Targeting EGFR and PI3K pathways in ovarian cancer.
Topics: Antibiotics, Antineoplastic; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Triazines; Tumor Cells, Cultured | 2013 |
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cluster Analysis; Disease Models, Animal; Disease Progression; Female; Humans; Mice; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Proteomics; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530).
Topics: Animals; Anoikis; Antineoplastic Agents; Benzodioxoles; Cadherins; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; Female; Fluorescent Antibody Technique; Humans; Mice; Ovarian Neoplasms; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers.
Topics: Calcium Channel Blockers; Calcium Channels, T-Type; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Female; Humans; Ovarian Neoplasms; Quinazolines; Structure-Activity Relationship | 2013 |
Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.
Topics: Allosteric Regulation; Antineoplastic Agents; Ascites; Autophagy; Benzylamines; Cell Line, Tumor; Cell Survival; Chloroquine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Spheroids, Cellular | 2014 |
Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Ovarian Neoplasms; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Quinazolines; Receptors, G-Protein-Coupled; Signal Transduction; Triazoles; Tyrphostins; Xenograft Model Antitumor Assays | 2014 |
An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade.
Topics: Adult; Aged; Antineoplastic Agents; Benzodioxoles; Cell Cycle; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Ovarian Neoplasms; Quinazolines; src-Family Kinases; Survival Analysis | 2014 |
Reply to B. Freidlin et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Transparency in interim monitoring.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Screening and identification of small molecule inhibitors of ErbB2-induced invasion.
Topics: Antineoplastic Agents; Cathepsin L; Female; Humans; Lapatinib; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
Drug combo may be effective in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines | 2014 |
Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinase B; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Humans; Organophosphates; Ovarian Neoplasms; Ovary; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines | 2015 |
Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Extracellular Matrix; Female; Humans; Mice, SCID; Molecular Targeted Therapy; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Spheroids, Cellular; Tumor Cells, Cultured; Tyrphostins; Xenograft Model Antitumor Assays | 2015 |
Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Cell Nucleus; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-6; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Protein Transport; Quinazolines; STAT3 Transcription Factor; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Cediranib aims for a comeback.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Female; Humans; Myelodysplastic Syndromes; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Protein-Tyrosine Kinases; Quinazolines; United Kingdom; United States; Uterine Cervical Neoplasms; Vaginal Fistula; Vascular Endothelial Growth Factor A; Weight Loss | 2015 |
Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Humans; Janus Kinases; Mice; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Small Molecule Libraries; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2015 |
Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Quinazolines; Xenograft Model Antitumor Assays | 2015 |
Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.
Topics: Afatinib; Amino Acid Sequence; Animals; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Molecular Structure; NF-kappa B; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sequence Homology, Amino Acid; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quinazolines | 2015 |
Evodiamine from Evodia rutaecarpa induces apoptosis via activation of JNK and PERK in human ovarian cancer cells.
Topics: Adenine; Anthracenes; Apoptosis; Caspase 3; Cell Line, Tumor; eIF-2 Kinase; Evodia; Female; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Membrane Potential, Mitochondrial; Ovarian Neoplasms; Poly(ADP-ribose) Polymerases; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2016 |
[Evodiamine induces extrinsic and intrinsic apoptosis of ovarian cancer cells via the mitogen-activated protein kinase/phosphatidylinositol-3-kinase/protein kinase B signaling pathways].
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Drugs, Chinese Herbal; Evodia; Female; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines | 2016 |
VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Benzimidazoles; Caspases; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cinnamates; Drug Synergism; Endoplasmic Reticulum Stress; Female; Humans; Ovarian Neoplasms; Ovary; Quinazolines; Thiourea; Valosin Containing Protein | 2016 |
PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.
Topics: Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factor 2; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Models, Biological; Ovarian Neoplasms; Phosphorylation; Quinazolines; Reproducibility of Results; RNA, Messenger; RNA, Small Interfering; Securin; src-Family Kinases | 2016 |
Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells.
Topics: Amphiregulin; Antigens, CD; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease-Free Survival; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Ligands; Membrane Proteins; Neoplasm Invasiveness; Ovarian Neoplasms; Protein Binding; Quinazolines; RNA Interference; Signal Transduction; Snail Family Transcription Factors; Time Factors; Tyrphostins | 2016 |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Extracellular Space; Female; Fluorescent Antibody Technique; Humans; Intracellular Space; Lapatinib; Maytansine; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Protein Domains; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Tissue Array Analysis; Trastuzumab; Uterine Neoplasms | 2017 |
Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Cyclin D1; DNA, Complementary; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoblotting; Immunoprecipitation; Neoplasms; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Repressor Proteins; RNA, Small Interfering; Sequence Analysis, DNA; Signal Transduction | 2008 |
Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasms; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Reproducibility of Results; Tumor Cells, Cultured | 2009 |
Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.
Topics: Butadienes; Cell Line, Tumor; Cell Movement; CSK Tyrosine-Protein Kinase; Cyclooxygenase 2; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Lysophospholipids; Nitriles; Ovarian Neoplasms; Pertussis Toxin; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Quinazolines; Receptors, Lysophosphatidic Acid; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP2 Subtype; Signal Transduction; src-Family Kinases; Transcriptional Activation; Tyrphostins | 2008 |
Cell motility and spreading are suppressed by HOXA4 in ovarian cancer cells: possible involvement of beta1 integrin.
Topics: Analysis of Variance; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Shape; Enzyme Inhibitors; Female; Fibronectins; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Immunohistochemistry; Integrin alpha5; Integrin beta1; Ovarian Neoplasms; Quinazolines; RNA, Small Interfering; Signal Transduction; Transcription Factors; Tyrphostins | 2009 |
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Piperidines; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Chromones; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Fucosyltransferases; Gefitinib; Humans; Lewis Blood Group Antigens; Morpholines; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2010 |
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Female; Half-Life; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Random Allocation; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2010 |
The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2.
Topics: Cell Line, Tumor; Dimerization; DNA Primers; ErbB Receptors; Female; Humans; Immunoblotting; Microscopy, Confocal; Mutation; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Polymerase Chain Reaction; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; RNA, Messenger; Tyrphostins | 2010 |
A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity.
Topics: Animals; Antinematodal Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA; DNA Damage; Drug Delivery Systems; ErbB Receptors; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Nitrogen Mustard Compounds; Ovarian Neoplasms; Quinazolines; Triazenes; Vulvar Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Heart; Humans; Lapatinib; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Razoxane; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cetuximab; Endosomal Sorting Complexes Required for Transport; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Nude; Ovarian Neoplasms; Prognosis; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2011 |
Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Colloids; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Nanocapsules; Ovarian Neoplasms; Paclitaxel; Quinazolines; Treatment Outcome | 2012 |
MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Topics: Adenocarcinoma, Clear Cell; Animals; Apoptosis Regulatory Proteins; Benzimidazoles; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Ovarian Neoplasms; Phosphoproteins; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Topics: Benzamides; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cyclohexanones; Disease-Free Survival; ErbB Receptors; Female; Humans; Interleukin-6; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Plasminogen Activator Inhibitor 1; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Microenvironment; Tyrphostins | 2012 |
Cytotoxic potential of novel 6,7-dimethoxyquinazolines.
Topics: Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Female; HCT116 Cells; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Mass Spectrometry; Ovarian Neoplasms; Quinazolines; Spectrophotometry, Infrared; Structure-Activity Relationship | 2012 |
A time-series DDP for functional proteomics profiles.
Topics: Bayes Theorem; Biomarkers, Tumor; Biometry; Cell Line, Tumor; Data Interpretation, Statistical; ErbB Receptors; Female; Humans; Lapatinib; Linear Models; Markov Chains; Models, Statistical; Monte Carlo Method; Multivariate Analysis; Ovarian Neoplasms; Protein Array Analysis; Proteomics; Quinazolines; Signal Transduction; Statistics, Nonparametric | 2012 |
Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2012 |
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dogs; Female; Haplorhini; HL-60 Cells; Humans; Leukemia; Mice; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2012 |
The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Matrix Metalloproteinases; Mice; Mice, Nude; Neoplasm Metastasis; Ovarian Neoplasms; Phosphorylation; Pyrrolidines; Quinazolines; Receptor, Endothelin A; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2012 |
Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluoresceins; Fluorescent Dyes; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Phenotype; Piperidines; Protein Kinase Inhibitors; Quinazolines; Rhodamine 123; Time Factors | 2012 |
The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials.
Topics: Adenocarcinoma, Papillary; Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Phthalazines; Piperazines; Quinazolines; Uterine Cervical Neoplasms | 2012 |
Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
Topics: ADAM Proteins; ADAM17 Protein; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cetuximab; Doxorubicin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Ovarian Neoplasms; Ovary; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2012 |
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice; Ovarian Neoplasms; Protein Binding; Protein Transport; Quinazolines; Receptors, Estrogen; src-Family Kinases; Xenograft Model Antitumor Assays | 2012 |
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Cystadenocarcinoma, Mucinous; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dihematoporphyrin Ether; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Photochemotherapy; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor | 2012 |
Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.
Topics: Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Cytological Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinase B; Carboplatin; Carcinoma; Caspase 3; Caspase 7; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Female; Humans; Organophosphates; Ovarian Neoplasms; Polyploidy; Quinazolines | 2013 |
Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Benzamides; Carcinoma; Cell Line, Tumor; Diphenylamine; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Cell Division; Cytokines; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Growth Substances; Humans; Immunoenzyme Techniques; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, SCID; Ovarian Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Transforming Growth Factor alpha; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells.
Topics: Adenocarcinoma; Apoptosis; Benzothiazoles; Cell Division; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Humans; Neoplasm Proteins; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Tretinoin; Tumor Cells, Cultured; Tyrphostins | 2003 |
Inhibitors that target protein kinases for the treatment of ovarian carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Catechols; Cell Cycle; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Nitriles; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Time Factors; Tumor Cells, Cultured; Tyrphostins | 2003 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; ErbB Receptors; Female; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Methylation; Ovarian Neoplasms; Promoter Regions, Genetic; Quinazolines; Receptor, ErbB-2; Receptors, Retinoic Acid; RNA, Messenger | 2005 |
Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.
Topics: Adamantane; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Caspase 8; Caspases; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cinnamates; DNA Damage; Drug Synergism; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Signal Transduction; Vulvar Neoplasms | 2005 |
Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Endothelin A Receptor Antagonists; Endothelin-1; Enzyme Induction; ErbB Receptors; Female; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Peptides, Cyclic; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, Endothelin A; Signal Transduction; Transcriptional Activation; Tyrphostins | 2004 |
BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
Topics: Animals; Apoptosis; Biological Transport; Carrier Proteins; Cell Proliferation; Choriocarcinoma; Enzyme Inhibitors; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Idoxuridine; Iodine Radioisotopes; Leukemia L1210; Lung Neoplasms; Membrane Transport Proteins; Mice; Mice, Nude; Ovarian Neoplasms; Quinazolines; Receptors, Cell Surface; Reduced Folate Carrier Protein; Thymidylate Synthase; Tissue Distribution; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation.
Topics: Animals; Antigen Presentation; Antigens, Surface; Apoptosis; Aspirin; Cell Line, Tumor; Cell Membrane; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Enzyme Activation; Enzyme Induction; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fas Ligand Protein; Female; Flavonoids; Humans; Lymphocyte Activation; Lymphocytes; Lysophospholipids; Membrane Glycoproteins; Nitrobenzenes; Ovarian Neoplasms; Quinazolines; Signal Transduction; Sulfonamides; Tumor Necrosis Factors; Tyrphostins | 2006 |
New agents and new formulations for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Dioxoles; Erlotinib Hydrochloride; Female; Humans; Isoquinolines; Ovarian Neoplasms; Predictive Value of Tests; Quinazolines; Recurrence; Remission Induction; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A | 2005 |
Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
Topics: Acetylation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chromones; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Morpholines; Neoplasm Proteins; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survivin; Time Factors | 2006 |
Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinase 1; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Quinazolines; Receptor Protein-Tyrosine Kinases; Survivin | 2006 |
Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; CpG Islands; DNA Methylation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Quinazolines; Receptors, Retinoic Acid; RNA Processing, Post-Transcriptional; Transcription, Genetic; Tyrphostins; Up-Regulation | 2007 |
Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; CA-125 Antigen; Cell Growth Processes; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Ovarian Neoplasms; Quinazolines; Radioimmunoassay | 2007 |
[The regulation of EKI-785 to the growth of U937 cell line].
Topics: Apoptosis; Blotting, Western; Cell Proliferation; ErbB Receptors; Female; Humans; Mitogen-Activated Protein Kinase Kinases; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; U937 Cells | 2006 |
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
Topics: Animals; Antineoplastic Agents; Cadherins; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neoplasm Invasiveness; Ovarian Neoplasms; Pyrrolidines; Quinazolines; Receptor, Endothelin A | 2007 |
In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Humans; Indicators and Reagents; Ovarian Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Neoplasm; Signal Transduction; Solutions | 2008 |
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Squamous Cell; Ovarian Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2008 |
Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Female; Mice; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
Implications of EGFR inhibition in ovarian cancer cell proliferation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Base Sequence; Cell Growth Processes; Cell Line, Tumor; Cetuximab; ErbB Receptors; Female; Gefitinib; Humans; Molecular Sequence Data; Mutation; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Topics: Animals; Antineoplastic Agents; Carrier Proteins; Deoxyuracil Nucleotides; Drug Resistance; Female; Folate Receptors, GPI-Anchored; Folic Acid; Folic Acid Antagonists; Humans; Kinetics; Leukemia L1210; Lymphocytes; Methotrexate; Mice; Neoplasm Proteins; Ovarian Neoplasms; Peptide Synthases; Polyglutamic Acid; Proteins; Quinazolines; Receptors, Cell Surface; Thiophenes; Thymidylate Synthase; Thymine Nucleotides; Tumor Cells, Cultured | 1995 |
Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Southern; Blotting, Western; DNA; DNA, Neoplasm; Drug Resistance; Female; Folic Acid; Humans; Lymphocytes; Molecular Sequence Data; Neoplasm Proteins; Ovarian Neoplasms; Polymerase Chain Reaction; Proteins; Quinazolines; RNA; RNA, Neoplasm; Thiophenes; Thymidylate Synthase; Transcription, Genetic; Tumor Cells, Cultured | 1995 |
Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
Topics: Aminopterin; Animals; Carrier Proteins; Cell Division; Female; Folate Receptors, GPI-Anchored; Folic Acid; Folic Acid Antagonists; Glutamates; Haplorhini; Humans; Kidney; Leucovorin; Methotrexate; Nasopharyngeal Neoplasms; Ovarian Neoplasms; Quinazolines; Receptors, Cell Surface; Tetrahydrofolates; Thiophenes; Tumor Cells, Cultured | 1995 |
Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; Folic Acid; Folic Acid Antagonists; Humans; Male; Ovarian Neoplasms; Quinazolines; Testicular Neoplasms; Thiophenes; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1995 |
Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Humans; Ovarian Neoplasms; Quinazolines; Tumor Cells, Cultured | 1996 |
Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868.
Topics: Cell Division; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Transforming Growth Factor alpha; Tumor Cells, Cultured | 1999 |
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Folic Acid Antagonists; Glutamates; Humans; Indoles; Isoindoles; Methotrexate; Ovarian Neoplasms; Quinazolines; Thiophenes; Transfection; Tumor Cells, Cultured | 1999 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Cell Division; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; GRB2 Adaptor Protein; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Ovarian Neoplasms; Peptides, Cyclic; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase C; Proteins; Quinazolines; Receptor, Endothelin A; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1; Transcriptional Activation; Tumor Cells, Cultured; Tyrosine; Tyrphostins | 2000 |
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Topics: Antigens, CD; Autocrine Communication; Carcinoma; Cell Adhesion; Cell Movement; Cell Size; DNA, Antisense; DNA, Complementary; Enzyme Induction; Enzyme Inhibitors; ErbB Receptors; Extracellular Matrix Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha3; Integrin alpha6; Integrins; Laminin; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Neoplasm Proteins; Ovarian Neoplasms; Phenotype; Quinazolines; Signal Transduction; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transfection; Tumor Cells, Cultured | 2001 |
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Humans; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Oligodeoxyribonucleotides, Antisense; Ovarian Neoplasms; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Piperazines; Pyrimidines; Quinazolines; Receptor, ErbB-2; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Caffeine eliminates gamma-ray-induced G2-phase delay in human tumor cells but not in normal cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Breast Neoplasms; Caffeine; Calcium Channel Blockers; Calcium Signaling; Carcinoma; Chickens; Demecolcine; Drug Resistance; Female; Fibroblasts; G2 Phase; Gamma Rays; HeLa Cells; Humans; Mitosis; Neoplastic Stem Cells; Neurons; Ovarian Neoplasms; Phosphodiesterase Inhibitors; Quinazolines; Radiation Tolerance; Ryanodine; Ryanodine Receptor Calcium Release Channel; Thapsigargin; Tumor Cells, Cultured | 2002 |
Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa").
Topics: Animals; Cell Division; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line; Drug Resistance; Female; Genes; Humans; Methotrexate; Ovarian Neoplasms; Phenotype; Quinazolines; Quinidine; RNA, Messenger; Trimetrexate; Tumor Cells, Cultured; Verapamil | 1989 |